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ABSTRACT
Inflammation can be a causative factor for carcinogenesis or can result from a consequence 
of cancer progression. Moreover, cancer therapeutic interventions can also induce an 
inflammatory response. Various inflammatory parameters are used to assess the inflammatory 
status during cancer treatment. It is important to select the most optimal biomarker among 
these parameters. Additionally, suitable biomarkers must be examined if there are no 
known parameters. We briefly reviewed the published literature for the use of inflammatory 
parameters in the treatment of patients with cancer. Most studies on inflammation evaluated 
the correlation between host characteristics, effect of interventions, and clinical outcomes. 
Additionally, the levels of C-reactive protein, albumin, lymphocytes, and platelets were the 
most commonly used laboratory parameters, either independently or in combination with 
other laboratory parameters and clinical characteristics. Furthermore, the immune parameters 
are classically examined using flow cytometry, immunohistochemical staining, and enzyme-
linked immunosorbent assay techniques. However, gene expression profiling can aid in 
assessing the overall peri-interventional immune status. The checklists of guidelines, such as 
STAndards for Reporting of Diagnostic accuracy and REporting recommendations for tumor 
MARKer prognostic studies should be considered when designing studies to investigate the 
inflammatory parameters. Finally, the data should be interpreted after adjusting for clinically 
important variables, such as age and cancer stage.
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INTRODUCTION
Inflammatory response, which promotes the healing of injured tissues, is a physiological 
defense mechanism against foreign substances. Inflammation can be a causative factor in 
cancer development or can result from a consequence of cancer progression. Additionally, 
inflammation can be induced by cancer interventions and/or by the cancer-associated 
complications and subsequently affect the tumor recurrence, progression, and metastasis [1]. It 
is important to determine the molecular players involved in the inflammatory response against 
cancer cells to assess the inflammation status and to devise the best therapeutic strategy [2].
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Surgery is an invasive intervention for cancer treatment. Clinicians gather routine clinical and 
laboratory information perioperatively to predict the surgical outcomes. However, the clinical 
and laboratory information is sometimes insufficient to assess the inflammation status in 
patients. Hence, novel parameters must be investigated for a more reliable prediction of 
surgical outcomes. Currently, various inflammatory and nutritional parameters as well as 
the body weight-related data are used to evaluate the inflammatory response associated 
with therapeutic interventions. In a recent study, we compared multiple parameters and 
demonstrated that simple biomarkers, such as albumin level, body mass index (BMI), and 
neutrophil count were more effective in predicting surgical outcomes than sophisticated 
biomarkers, such as the prognostic nutritional index (PNI), nutritional risk index (NRI), 
and neutrophil-to-lymphocyte ratio (NLR) [3]. The results of the study suggested that low 
albumin level, high BMI, high neutrophil count are predictors of major complications, 
operative mortality and unfavorable recurrence-free survival, and unfavorable overall and 
recurrence-free survival, respectively. These observations indicated that we must reconsider 
the parameters currently used for determining the surgical outcome of patients. We reviewed 
the published literature for parameters used to determine inflammatory response in patients 
with cancer. Further, the parameters were classified to guide researchers to systematically 
evaluate the inflammatory response in patients.
FACTORS ASSOCIATED WITH INFLAMMATION IN 
PATIENTS WITH CANCER
We grouped the published studies into three groups (Table 1) [3-81]. The first group included 
studies that identified the characteristics of hosts exhibiting inflammation, the second group 
included studies that measured the effect of treatment interventions, and the third group 
included studies that predicted the outcomes of interventions.
Host factors
Among the various factors that affect inflammatory response, the inherent factors, such 
as sex, age, and obesity are well-known and are the most important host factors. Men and 
women exhibit differential immune response due to the difference in the number of X 
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Table 1. Studies on inflammatory response parameters in cancer
Host Intervention Outcomes
Inherence Behavior Disease Surgical Medical Prediction Prognosis
Sex [4-6] Immunosuppressive 
medication [12]
Chronic disease [16] Open surgery vs MIS 
[21-24]
Anesthesia, analgesia 
[30-32]
Morbidity and 
mortality [56-63]
Recurrence [68-72]
Age [7,8] Nutritional status 
[13]
Cancer progression 
[17]
Major vs minor 
surgery [1,25]
Fast track protocol 
[33-35]
Infection [64,65] Survival [12,26,73-81]
Obesity [3,9-11] Smoking [14] Psychiatric disease 
[18]
Emergency surgery 
[26,27]
Transfusion [36,37] Prediction of 
neoadjuvant 
response [66,67]
Exercise [15] Ischemia [19] Surgical stress 
[28,29]
Nutritional support* 
[38-44]
Sepsis [20] Steroid and other 
immune modulators 
[25,45-50]
Adjuvant/neoadjuvant 
treatment [51-53]
NSAID [54]
Statin [55]
MIS = minimally invasive surgery; NSAID = non-steroid anti-inflammatory drug.
*Includes enteral, parenteral, and immune-enhancing nutrition.
chromosomes and variations in sex hormones [4]. Estrogen promotes T helper cell type 2 
(Th2) and suppresses T helper cell type 1 (Th1) immune responses, whereas testosterone 
suppresses the Th2 immune response [5]. The Th1 immune responses are cell-mediated 
responses that target the intracellular pathogen, whereas Th2 responses are antibody-
mediated responses that target the extra-cellular pathogen. The analysis of differential 
immune response between the genders revealed that women have a lower risk of microbial 
infections and higher prevalence of autoimmune disease, whereas men have a higher 
susceptibility to systemic inflammatory response syndrome or infectious complications after 
surgery [6]. Age is also an important clinical parameter. The body's ability to distinguish 
between self and non-self cells decreases with age. Hence, decreased number of immune 
cells and weakened immune function associated with aging increase the susceptibility to 
malignancies and reactivation of chronic infections among aged individuals. Thus, several 
studies have evaluated the postoperative outcomes for elderly patients [7,8]. Obesity, which is 
generally measured by BMI, is associated with impaired immune function [9], inflammation 
[10], and complications following treatment interventions [11].
Other factors that may affect the inflammatory response and clinical outcomes include behavior- 
and disease-related characteristics, such as immunosuppressive medication usage [12], 
nutritional status [13], smoking status [14], exercise habits [15], presence of chronic disease [16], 
cancer stage [17], psychiatric condition [18], and presence of ischemia [19] or sepsis [20].
Intervention factors
Among the various therapeutic interventions, surgery is the most invasive intervention. 
The incision size or resection extent is directly correlated with the degree of surgical 
trauma. Hence, several studies are focused on developing novel surgical techniques that are 
associated with less surgical trauma and exhibit similar therapeutic efficacy. In the last few 
decades, comparative efficacy of open and laparoscopic surgery has been well studied [21]. 
The advantages of laparoscopic surgery include decreased surgical trauma and attenuated 
inflammatory response. The Th1/Th2 ratio is modulated to favor a decreased inflammatory 
response and decreased concentration of acute phase markers [22,23]. Recently, minimally 
invasive surgical procedures, such as reduced port laparoscopy and robotic surgery have been 
used to reduce the inflammatory response associated with open surgery [23,24].
The inflammatory response resulting from surgical intervention correlates with surgical 
trauma and is easy to predict. However, inflammatory responses resulting from other 
medical interventions are diverse and difficult to predict. Anesthetic techniques affect not 
only postoperative recovery but can also potentially impair the survival outcomes due to the 
suppression of inflammation [30,82,83]. Regional or epidural anesthesia is reported to be a 
factor that mitigates surgery-induced immunosuppression [31,32]. Moreover, peri-operative 
management [33-35], transfusion strategy [36,37], and pain management [32] are reported to 
considerably influence the inflammatory response.
Nutritional supplements, such as glutamine and arginine are used to enhance the 
immune response (referred to as immunonutrition) [38,39], while probiotics are used 
for perioperative modulation of the gut microbiome [40,41]. Nutrional supplements 
and probiotics have been extensively studied to determine their effect on the immune 
response and clinical outcomes. However, it is difficult to evaluate the effect of nutritional 
interventions on well-nourished patients. The nutritional interventions are most effective in 
patients exhibiting malnourishment [84,85].
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Finally, steroids are one of the most well studied drugs that are used to attenuate the immune 
response. Preoperative steroid administration is reported to markedly decrease systemic 
inflammatory cytokine release and improve the postoperative clinical course of patients, 
without adverse effects on immunity [45,46]. The immune modulators, such as dendritic 
cell-activated cytokine-induced killer cells [47], interleukin (IL)-2 [48], neutrophil elastase 
inhibitors [49], protease inhibitors [50], and recombinant human granulocyte colony-
stimulating factor [25] have been studied to determine their effectiveness during the peri-
intervention period.
Outcomes
The most classical clinical outcomes measured following therapeutic interventions, such as 
surgery, chemotherapy, or radiotherapy are complication rates and recovery time in short-
term [61], and survival without unfavorable events in long-term [71]. Additionally, some 
inflammation parameters including tumor-infiltrating lymphocytes or composite scores can 
be used for predicting the inflammation response following neoadjuvant chemo-radiation 
therapy [64,65] or for anticipating an infection [66] following an intervention.
APPROACHES FOR EVALUATING INFLAMMATORY 
PARAMETERS
Laboratory parameters
Historically, laboratory values are used to assess the inflammatory status of the patients 
(Table 2) [3,17,23,26,34,35,38,39,42,44,50,59,62,66,69,71,73-79,84,86-89,90-106]. Laboratory 
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Table 2. Laboratory parameters
Parameters
Single value Combined values
Positive APPs
CRP [34,39,71,86] NRS-2002 [3,44,84]
High sensitivity CRP [87,88] MUST [3]
Erythrocyte sedimentation rate [89] Skeletal muscle index [90]
Alpha 1-acid glycoprotein levels [91] NRI [3]
Serum amyloid A levels [92,93] SIRS criteria [50,94]
Alpha-1-antitrypsin levels [95] CRP/Albumin ratio [17,75]
Procalcitonin levels [23,62,96] GPS, modified GPS, hepatic GPS [17,26,66,79]
Fibrinogen levels [88,97] PNI [69,98]
Complement-C3 and C4 levels [35,44] Prognostic index [98]
APRI [99]
Negative APPs CONUT [78]
Albumin levels [3,100] Naples prognostic score [73]
Prealbumin levels [38,42] Canton score [101]
Retinol-binding protein levels [38,95] PLR [74,102]
Transferrin levels [39,95] NLR [59,74,77,102]
COP-NLR [76]
NMLR [103]
GLR [104]
LMR [105]
SII [106]
APP = acute phase protein; CRP = C-reactive protein; NRS = nutritional risk screening; MUST = malnutrition 
universal screening tool; NRI = nutritional risk index; SIRS = systemic inflammatory response syndrome; GPS 
= Glasgow prognostic score; PNI = prognostic nutritional index; APRI = aspartate aminotransferase/platelet 
count ratio index; CONUT = controlling nutritional status; PLR = platelet-to-lymphocyte ratio; NLR = neutrophil-
to-lymphocyte ratio; COP-NLR = combination of platelet count and neutrophil-to-lymphocyte ratio; NMLR = 
neutrophil-monocyte-to-lymphocyte ratio; GLR = granulocyte-to-lymphocyte ratio; LMR = lymphocyte-to-
monocyte ratio; SII = systemic immune-inflammation index.
parameters are economical to evaluate, easily measurable, repeatable, and ready to use in 
daily clinical practice. Among the various laboratory parameters, acute phase protein levels 
are the most relevant to determine the inflammatory status of patients. The levels of positive 
acute phase proteins increase, whereas those of negative acute phase proteins decrease 
during inflammation [107]. C-reactive protein (CRP) and albumin are the most commonly 
used positive and negative acute phase proteins, respectively. CRP is secreted from the liver 
and the CRP levels increase upon secretion of IL-6 by macrophages and T-cells. Although 
meta-analyses have revealed limited diagnostic value of CRP for diagnosing postoperative 
complications [108,109], CRP level is useful during follow-up as it has a short half-life.
The predominant protein in the blood serum is albumin. Albumin carries water-insoluble 
molecules necessary for various metabolic processes. Although albumin is reported to 
be a negative acute phase protein, hypoalbuminemia does not represent an increased 
inflammatory status in patients [110]. Hence, albumin level is used independently or in 
combination with other laboratory values to assess the nutritional status in patients [100].
The combination of CRP and albumin has been extensively studied for the prediction of 
survival [106,111], tumor recurrence [70,71], peri-operative mortality [58], and specific 
outcomes, such as central venous catheter-related bloodstream infection [66]. The predictive 
value of CRP and albumin combination is not conclusive due to the heterogeneity in results 
reported by different studies. However, the CRP and albumin levels are the most sensitive and 
reliable biomarkers among the various inflammation-based scores [98,111-113].
Currently, CRP, albumin, lymphocytes, or platelets are used in combination to predict the 
surgical outcomes. Fig. 1 shows the relationship among these parameters. However, the use 
of combinations of these four parameters without accounting for the clinical parameters 
can be misleading as these 4 parameters are not independent but associated with patient 
characteristics, such as age and cancer stage. Thus, combined parameters based on albumin 
may lose their predictive value after adjustment with patient characteristics [3,114]. As shown 
in Fig. 2, there is a correlation between albumin level, age, and cancer stage [115].
Immune parameters
Immune cells
Assessment of immune cells and cytokines is necessary to evaluate the immune 
response in patients (Table 3) [1,3,13,14,18,20,22,25,27,29,30,31,34,35,39,42-44,47,50-
54,60,63,67,72,79,80,81,85-88,90,91,93,95,97,103,116-132]. The innate immune response 
is rapid and does not require prior exposure to an antigen. This general, non-specific, and 
first-line defense system against foreign substances is mediated by the natural killer (NK) 
cells. In response to injury, macrophages and mast cells are the first host tissue cells that are 
activated, which subsequently coordinate the immune response. The adaptive immune cells 
mainly consist of B and T lymphocytes. The analysis of complete blood count (CBC) provides 
the crude numbers of neutrophils, granulocytes, lymphocytes, and platelets. However, 
evaluating the lymphocyte subpopulations of dendritic cells and T-cells is more complicated 
and requires flow cytometric analysis. The T-cells comprise cytotoxic T-cell and helper T-cell 
subpopulations, which can be further classified as Th1, Th2, Th17, and regulatory T cells. 
Cancer recurrence can be predicted by phenotyping and functional assay of lymphocytes 
from the peripheral blood and tumor lysate [68]. If fresh blood is not available, the immune 
status of tumor tissues can be evaluated by immunohistochemical staining. The advantage of 
using paraffin-embedded tissue blocks is that the long-term outcome of the treated patients 
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is already known. The tumor microenvironment is assessed by evaluating the lymphocytes 
[133-135], tumor-associated macrophages [72], and myeloid-derived suppressor cells [136].
Cytokines
The immune cells communicate with each other through signaling molecules or cell-to-cell 
communication, which involve toll-like receptors, B and T cell receptors and the complement 
system [137,138]. However, majority of the immune cells communicate through the secretion 
of cytokines. Cytokines are a category of cell-signaling proteins that regulate various 
immunological functions. Various proteins, such as lymphokines (produced by lymphocytes), 
monokines (produced by monocytes), chemokines (regulate chemotactic activities between 
cells), interferons (involved in the antiviral activity), and interleukins function as cytokines. 
Several cytokine classifications were proposed based on the Th1/2 axis [139,140]: receptor 
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Fig. 1. Relationship among parameters. Parameters with continuous values (Green boxes) and with categorical values (Orange boxes). Detail of values are 
presented in Appendix 1. 
BMI = body mass index; MUST = malnutrition universal screening tool; NRS = nutritional risk screening; NRI = nutritional risk index; AST = aspartate transaminase; 
CRP = C-reactive protein; GPS = Glasgow prognostic score; CAR = C-reactive protein-to-albumin ratio; CONUT = controlling nutritional status; PI = prognostic 
index; PNI = prognostic nutritional index; WBC = white blood cell; APRI = aspartate aminotransferase/platelet count ratio index; NLR = neutrophil-to-lymphocyte 
ratio; NMLR = neutrophil-monocyte-to-lymphocyte ratio; LMR = lymphocyte-to-monocyte ratio; SII = systemic immune-inflammation index; GLR = granulocyte-to-
lymphocyte ratio; PLR = platelet-to-lymphocyte ratio; COP-NLR = combination of platelet count and neutrophil-to-lymphocyte ratio.
and cytokine structures [141], the position of cysteine residues [142], and pro-inflammatory 
or anti-inflammatory parameters [143].
Among these classifications, the functional classifications (Th1/2) and receptor structures 
is the most relevant grouping method (Table 4) [144]. The functional classification is widely 
used in clinical and experimental practice and categorize the cytokines based on their 
involvement in cellular immune responses (Th1) and antibody-mediated responses (Th2). 
The Th1 response is the principal immune mechanism underlying cellular immunity. Cell-
mediated immune response includes activation of monocytes and cytotoxic T lymphocytes 
against virus-infected cells, intracellular parasites, intracellular bacteria, and tumors [145]. 
The critical cytokines involved in type I response are interferon-gamma (IFN-γ) and IL-12. 
The mechanism underlying humoral immunity involves type II response. Humoral immune 
response includes the activation of eosinophils, mast cells, and B lymphocyte proliferation 
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Fig. 2. Relationship of albumin level with age according to stage. Each point represents age and albumin level 
of a patient. Linear regression of each stage group shows that mean albumin level at same age decrease as the 
disease progresses. Dataset from Lee et al. [115].
Table 3. Immune parameters
Parameter
Immune cells Peripheral blood
Lymphocyte counts [22,85]
Neutrophil counts [3,51,79,116]
Monocyte counts [103]
Dendritic cell counts [54,80]
NK cell counts [117,118]
T lymphocyte subpopulation counts [42,44,53,81]
B lymphocyte counts [53,117,118]
Tissue
Tumor-infiltrating lymphocyte levels [52,81]
Tumor-associated macrophage levels [72]
Mast cell density positive to tryptase [119]
Other fluid
Peritoneal fluid: Lymphocyte subsets and HLA-DR expression [120]
(continued to the next page)
and differentiation. The key cytokines involved in mediating type II response are IL-4 and IL-
10. Type II response is immunosuppressive and is observed after extensive injury in patients 
with cancer undergoing surgery. IL-4 and IL-10 inhibit type I response, whereas IFN-γ inhibits 
type II response. As these 2 response mechanisms may inhibit each other, the ratio of the 
major molecular players involved in type I and type II responses (the ratio of IFN-γ or IL-12/
IL-4 or IL-10) can be useful biomarkers [30,31,121,122,143,145].
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Parameter
Cytokines Peripheral blood
TNF-α levels [22,39,50]
IFN-γ levels [22,53,54]
Th1/Th2 ratio [30,31,121,122]
IL-1 levels [1]
IL-2 levels [53,123]
IL-4 levels [1,53,123]
IL-5 levels [123]
IL-6 levels [22,34,43,50]
IL-8 levels [18,116]
IL-9 levels [124]
IL-10 levels [29,63]
IL-12 levels [20,63]
IL-13 levels [53]
IL-15 levels [27]
IL-17 levels [30,54]
IL-18 levels [13]
Levels of multiple cytokines [47,124]
TNF-R levels [25,125]
TNF-R inhibitor levels [125,126]
IL-2 receptor levels [42]
IL-1 receptor antagonist levels [25,60,95]
IL-6 soluble receptor levels [127]
Adipocytokine leptin levels [93]
Immunosuppressive acidic protein levels [127]
Neopterin levels [39]
Levels of globulins including IgG, IgA, and IgM [35,44,86]
Proapoptotic protein-soluble Fas levels [126]
MCP-1 levels [97]
Calprotectin levels [90]
Levels of DAMPs (HSP-S100A-HMGB) [128]
Neutrophil elastase levels [67,88,116]
Other fluid
Alveolar lavage: levels of multiple cytokines [129]
Peritoneal lavage: levels of multiple cytokines [120]
Gene expression Peripheral blood
HLA-DR expression on monocytes [1,25,29,34]
mRNA expression of TLR2-TLR4 [91]
Expression of histamine receptors [130]
Other fluid
Alveolar lavage: RT-PCR for proinflammatory cytokines [14]
Others NK activity [13,15,36,43]
Lymphocyte oxidative activity [131]
Lymphocyte proliferation [25,43]
Phagocytic capacity [132]
Skin-prick tests [130]
Oxidative stress-antioxidant capacity [87]
NK = natural killer; HLA-DR = human leukocyte antigen-DR isotype; TNF = tumor necrosis factor; INF, interferon; 
Th = T helper; IL = interleukin; Ig = immunoglobulin; MCP-1 = monocyte chemoattractant protein-1; DAMP = 
damage-associated molecular patterns; TLR = Toll-like receptors; RT-PCR = real-time polymerase chain reaction.
Table 3. (Continued) Immune parameters
Gene expression
Flow cytometry and enzyme-linked immunosorbent assay are used for classical hypothesis-
driven studies. These are confirmatory techniques that are specific for the selected 
parameters (Fig. 3) [23,24,33,45-47,86,122,123,125,146-152]. However, measuring only 
selected immune responses does not provide information on the global changes associated 
with complex immune response. The inflammatory response status can be evaluated using 
gene expression. A study on patients with colon cancer undergoing surgery demonstrated 
that the genes associated with antigen presentation, general T-cell receptor signaling, and 
granzyme-B encoding for NK and CD8+ T-cells are downregulated [153]. Additionally, the 
study revealed that the genes encoding cytokines (IL-1B, IL-6, tumor necrosis factor [TNF], 
and IL-10), CRP, growth factor, and matrix metalloproteinase were upregulated [153]. This 
indicated downregulation of T-cell receptor signaling, antigen presentation, and NK cell 
activity and promotion of metastases, growth, and angiogenesis. The strength of this high-
throughput study enables us to assess the “genomic storm” of peri-operative changes in gene 
expression. The gene expression changes indicate not only immune system activation but 
also the inability to maintain homeostasis. Another study demonstrated the downregulation 
of differentiation/clonal expansion of T cytotoxic cell and T-cell surface markers and up-
regulation of IL-18 and IL-10 signaling pathways [154].
It is intriguing that transcriptomic data from a bulk tumor can be used to predict the status 
of immune cell infiltration. Fig. 4 illustrates a heatmap of 22 types of immune cell infiltration 
inferred from The Cancer Genome Atlas stomach adenocarcinoma gene expression cohort 
[155]. Cell-type identification by estimating relative subsets of RNA transcripts (CIBERSORT) 
is a deconvolution algorithm that uses a set of reference gene expression values to support 
the vector regression inference immune cell types in data from mixed cell types of bulk tumor 
samples [156].
Guidelines
Effective data collection is necessary to identify the relevant parameters associated with the 
inflammatory response. REporting recommendations for tumor MARKer prognostic studies 
(REMARK) and STAndards for Reporting of Diagnostic accuracy studies (STARD) provide 
suggested guidelines as checklists to supply relevant information necessary for the design 
and reporting of prognostic markers and diagnostic accuracy [157,158]. STARD guidelines are 
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Table 4. Representative cytokines of each classification
Representative cytokine Th1/2 Receptor structure Example*
IL-2† Th1 Type 1, common r-chain† IL-7,9,15,21
IL-6 Th1 Type 1, IL-6 like cytokines IL-11,30
IL-12 Th1 Type 1, IL-12 subfamilies IL-23, 27, 35
IL-17 Th1 Type 1, IL-17R
TNF-α Th1 Type 1, TNF TNF-β
IFN-γ Th1 Type 2, IFN
IL-8 Th1 Chemokine R
IL-3 Th1 & Th2 Type 1, common-b-chain IL-5, GM-CSF
IL-4† Th2 Type 1, common r-chain† IL-13
IL-1 Th2 Type 1, IG IL-18, 33, 36, 37, 38
IL-10 Th2 Type 2, IL-10 subfamily IL-19, 20, 22, 24, 26
MCP-1 Th2 Chemokine R
TGF-β Th2 TGF receptor family
IL = interleukin; Th = T helper; TNF = tumor necrosis factor-alpha; IFN, interferon; GM-CSF = granulocyte-macrophage 
colony-stimulating factor; MCP-1 = monocyte chemoattractant protein-1; TGF = transforming growth factor.
*Examples according to receptor structure; may not show the same Th1/2 balance as representative cytokines; 
†IL-2 and IL-4 share the same receptor structure but show opposite Th1/2 balance.
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focused on the preciseness of a parameter compared to the gold-standard. The prediction of 
complications based on preoperative or immediate postoperative laboratory values provides 
a good example of STARD guidelines [108,159]. REMARK guidelines are used to predict the 
survival of patients undergoing a test or treatment. A preoperative neutrophil-to-lymphocyte 
ratio predicting long term survival would be an example of application of REMARK 
guidelines [77]. As REMARK guidelines are related to survival, it is important to assess 
time-to-event and associated clinical factors such as age, sex, and disease status. These two 
guidelines share the essential factors of describing a good study and defining other unique 
requirements. We compared the checklists of STARD and REMARK guidelines to guide good 
study design and data analysis (Table 5).
Interpretation of data
A prerequisite for the identification of a novel biomarker is the valid interpretation of 
data. We suggest that three issues must be elaborated during the data interpretation. First, 
inherent characteristics of patients, such as age, sex, and disease status, should be adjusted 
using a multivariate analysis for assessing the value of inflammatory parameters. This is to 
prevent the misinterpretation of data. The level of albumin, which is required for calculation 
of PNI, is highly correlated with age and cancer stage, such that the diagnostic value of PNI 
decreases after adjustment [3,115]. Second, most of the inflammatory parameters exhibit 
continuous variation. For any regression analysis, it is always preferable to treat continuous 
parameters as continuous. However, these parameters are converted to categorical values to 
enter into regression models in most studies. An arbitrary decision for the cut-off values may 
result in a misinterpretation of data and hinders their routine use in clinical practice. Third, 
a value could be interpreted differently in the context of the inflammatory response. Skewing 
Th1/Th2 immune function, proportion of regulatory T-cells among helper T-cells, and a 
sequential change of parameters following surgery are good examples.
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B cells memory
Plasma cells
T cells follicular helper
T cells CD8
T cells CD4 memory activated
Macrophages M1
Monocytes
T cells gamma delta
Macrophages M2
NK cells activated
Mast cells resting
B cells naive
T cells CD4 naive
T cells regulatory (Tregs)
Macrophages M0
T cells CD4 memory resting
Dendritic cells resting
Dendritic cells activated
NK cells resting
Mast cells activated
Eosinophils
Neutrophils
Fig. 4. Unsupervised clustering of inferred immune fraction using leukocyte signature matrix in the cancer genome atlas stomach adenocarcinoma (TCGA-STAD) 
transcriptomic dataset (n=450). Integrative transcriptomic analysis enables the identification of distinct immune landscapes associated clinical phenotypes 
using the fraction of infiltrated immune subsets in each sample as well as the evaluation of oncogenic pathway specific to each sample.
INFLAMMATION AND GASTRIC CANCER
Various aspects of the relationship between inflammation and gastric cancer treatment have 
also been studied. Microenvironment generated by unresolved inflammation is involved in 
the pathogenesis of non-cardia gastric cancer [160]. The host factors, such as age, obesity, 
and nutritional status are reported to be associated with the outcome of gastric cancer 
treatment [161,162]. Minimally invasive surgery has been widely used and several studies, 
including randomized trials have demonstrated the higher efficacy of laparoscopic and 
robot-assisted surgeries compared to open surgery [163,164]. Anesthesia techniques and 
perioperative nutritional support have enhanced postoperative recovery after the guidelines 
for gastric cancer surgery were published [165,166]. Laboratory and immune parameters 
are reported to be a predictor of outcomes in several studies, including our earlier studies 
[3,101,115].
Inflammation is the common condition that was evaluated in all these studies. The purpose 
of cancer research should not only include killing cancer cells but also patient care. However, 
there are limited studies that have comprehensively evaluated the correlation between high-
quality clinical parameters, immune cells, and cytokines. We believe that sharing insights of 
inflammation during the disease process and biomedical literacy of clinicians in molecular, 
genetic, and immune mechanisms will change the way of providing care to patients with 
gastric cancer in the future [153,155].
CONCLUSIONS
There has been an increased interest in predicting short- and long-term treatment 
outcomes. To show a significant difference during the hypothesis test, study aim, selection 
of parameters, and interpretation of results should be carefully performed, as recommended 
in this review. Although not discussed here, issues associated with the sources of examined 
material (peripheral blood, tumor lysate, or tumor draining vein) and timing of examination 
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Table 5. Guidelines for biomarker studies
Structure Common guidelines STARD-specific guidelines REMARK-specific guidelines
Introduction Background, objective, and hypothesis
Methods • Eligibility criteria • Participant identification methods • Description of biological material used
• Participants chosen for the study • Rationale for reference standard • Clinical endpoints examined
• Detailed protocol sufficient to replicate •  List of all candidate variables initially 
examined•  Study performer, readers, or assessors blinded to 
identifying information
• Data collection methods (retrospective vs prospective)
• Sample size determination
• Missing data handling
• Rationale for cut-offs
Results • Study flow
• Characteristics of patients
•  Relation of index test (marker) and reference standard 
(prognosis)
•  Estimation of accuracy and precision (STARD) or 
confidence intervals (REMARK)
•  Time interval between index test 
and reference standard
•  Univariable analyses revealing the 
correlation between the marker and 
outcome
•  Adverse events due to the index 
test or the reference standard
•  Confidence intervals from an analysis in 
which the marker and standard prognostic 
variables are included
• Results of further investigations
Discussion •  Limitations, implications for practice, and future 
research
•  Interpret the results in the context of the 
pre-specified hypotheses
STARD = STAndards for Reporting of Diagnostic accuracy studies; REMARK = REporting recommendations for tumor MARKer prognostic studies.
(pre- or immediate post-interventional) are also important. Selection of when, how, and what 
to measure during the intervention may critically affect the decisions and clinical outcomes. 
Thus, peri-interventional inflammatory responses in patients with cancer require further 
exploration by a clinical oncologist.
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APPENDIX 1
Parameters with continuous values (Green boxes in Fig. 1)
NRI (nutritional risk index): 15.19 × albumin level (g/dL) + 41.7 × (present weight/usual weight)
CAR (C-reactive protein [CRP]-to-albumin ratio): serum CRP level (mg/dL)/serum albumin level (g/dL)
PNI (prognostic nutritional index): 10 × albumin level (g/dL) + (0.005 × lymphocyte count [number/mm3])
SII (systemic immune-inflammation index): (platelet count × neutrophil count)/lymphocyte count
NLR (neutrophil-to-lymphocyte ratio): neutrophil count/lymphocyte count
PLR (platelet-to-lymphocyte ratio): platelet count/lymphocyte count
GLR (granulocyte-to-lymphocyte ratio): granulocyte count/lymphocyte count
LMR (lymphocyte-to-monocyte ratio): lymphocyte count/monocyte count
NMLR (neutrophil-monocyte-to-lymphocyte ratio): (neutrophil count × monocyte count)/lymphocyte count
APRI (aspartate aminotransferase-to-platelet count ratio): Aspartate aminotransferase level (units/L)/platelet count
Parameters with categorical values (Orange boxes in Fig. 1)
NRS (nutritional risk screening 2002):
Summation of points for (1) nutritional status (0, weight loss ≤5% in 3 months; 1, >5% in 3 months; 2, >5% in 2 months; 3, >5% 
in 1 month), (2) severity of disease (0, normal; 1, hip fracture; 2, major abdominal surgery; 3, head injury and APACHE score 
≥10), and (3) age (0, <70 years; 1, ≥70 years)
MUST (malnutrition universal screening tool):
Summation of points for (1) body mass index (BMI) score (0, BMI ≥20 kg/m2; 1, BMI=18.5–20 kg/m2; 2, BMI ≤18.5 kg/m2), (2) weight 
loss in 3 months (0, ≥5%; 1, 5%–10%; 2, ≥10%), and (3) acute disease effect score (0, normal; 2: no nutritional intake >5 days)
COP-NLR (combination of platelet count and neutrophil-to-lymphocyte ratio): Composite score of platelet count and 
NLR (Score 0/1/2)
COP-NLR 0: normal platelet count (<300 × 103/mL) or a normal NLR (<3)
COP-NLR 1: elevated platelet count (>300 × 103/mL) or an elevated NLR (>3)
COP-NLR 2: elevated platelet count (>300 × 103/mL) and an elevated NLR (>3)
PI (prognostic index): Composite score of serum CRP and white blood cell (WBC) count (Score 0/1/2)
PI 0: normal CRP levels (<1.0 mg/dL) and normal WBC count (<11 × 109/L)
PI 1: elevated CRP levels (>1.0 mg/dL) or elevated WBC count (>11 × 109/L)
PI 2: elevated CRP levels (>1.0 mg/dL) and elevated WBC count (>11 × 109/L)
GPS (Glasgow prognostic score): Composite score of serum CRP and albumin levels (Score 0/1/2)
GPS 0: Normal albumin (>3.5 g/dL) and normal CRP (<1.0 mg/dL) levels
GPS 1: Low albumin (<3.5 g/dL) or elevated CRP (>1.0 mg/dL) levels
GPS 2: Both low albumin (<3.5 g/dL) and elevated CRP (>1.0 mg/dL) levels
mGPS (modified Glasgow prognostic score): Composite score of serum CRP and albumin levels (Score 0/1/2)
mGPS 0: Normal CRP levels (≤1.0 mg/dL) regardless of albumin levels
mGPS 1: Normal albumin (≥3.5 g/dL) and elevated CRP (>1.0 mg/dL) levels
mGPS 2: Low albumin (<3.5 g/dL) and elevated CRP (>1.0 mg/dL) levels
Canton score: Composite score of PNI, NLR, and platelet count (Score 0/1/2/3)
Canton 0: elevated PNI (≥48), low NLR (≤1.83), and normal platelet count (≤300 × 103/mL)
Canton 1: presence of one among the predictors of poor outcome: low PNI (<48), elevated NLR (>1.83), and elevated platelet 
count (>300 × 103/mL)
Canton 2: presence of two among the predictors of poor outcome: low PNI (<48), elevated NLR (>1.83), and elevated platelet 
count (>300 × 103/mL)
Canton 3: low PNI (< 48), elevated NLR (> 1.83), and elevated platelet count (> 300 × 103/mL)
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Naples prognostic score: Composite score of the serum albumin level, total cholesterol level, NLR, and LMR (Score 
0/1/2)
Summation of points for (1) serum albumin level (0, ≥4 g/dL; 1, <4 g/dL), (2) Total cholesterol level (0, >180 mg/dL; 1, ≤180 mg/
dL), (3) NLR (0, ≤2.96; 1, >2.9), and (4) LMR (0, >4.44; 1, ≤4.44). The sum of all four points: 0, Naples group 0; 1 or 2, Naples 
group 1; 3 or 4, Naples group 2
CONUT (controlling nutritional status): Composite score of the serum albumin level, lymphocyte count, and total 
cholesterol value
Sum of the albumin score (scores 1, 2, 4, and 6 for 3.5–4.5, 3–3.49, 2.5–2.9, and < 2.5 g/dL, respectively), lymphocyte score 
(scores 0, 1, 2, and 3 for ≥ 1600, 1200–1599, 800–1199, and < 800/mm3, respectively), and total cholesterol score (scores 0, 1, 2, 
and 3 for >180, 140–180, 100–139, and < 100 mg/dL, respectively). The summation of all three scores: 0–1, Normal; 2–4, Light; 
5–8, Moderate; 9–12, Severe
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